Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars PlatformPR Newswire·2 days ago, 11:08 PMSDZNY+3.13%026960.00%
HENLIUS Reaches Global Strategic Partnership With Sandoz, Invoiceable Amt Expected to Reach USD100.5M This YearAASTOCKS News·Aug 16 at 08:06 PM026960.00%SDZNY+3.13%
Henlius Strikes Global Biosimilar Alliance with SandozTip Ranks·Aug 16 at 07:09 PM026960.00%SDZNY+3.13%
Sandoz partners with Henlius on up to 10 biosimilars in USD 322 million dealPUBT·Aug 16 at 07:00 PMSDZNY+3.13%026960.00%
Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform | SDZNY Stock NewsStockTitan·Aug 16 at 03:08 PM026960.00%SDZNY+3.13%
Shanghai Henlius Biotech (SEHK:2696) Advances Oncology Pipeline, Is It Still 64% Below Fair Value?Simplywall·Aug 9 at 06:33 PM026960.00%
Shanghai Henlius says China NMPA clears HLX43-bevacizumab trial in advanced solid tumorsPUBT·Jul 31 at 03:31 AM026960.00%
Shanghai Henlius Biotech Grants New Share Options and RSUs to Strengthen IncentivesTip Ranks·Jul 17 at 09:37 AM026960.00%
Henlius Doses First Patient in Global Trial of Nivolumab Biosimilar HLX18Tip Ranks·Jul 16 at 03:40 AM026960.00%
Shanghai Henlius says China NMPA clears Phase 1 trial of HLX37 with chemo or HLX43 in solid tumorsPUBT·Jul 10 at 03:31 AM026960.00%
Henlius Doses First Patient in Phase 1 Trial for Cetuximab Biosimilar HLX05-NTip Ranks·Jul 8 at 04:37 AM026960.00%
Shanghai Henlius doses first patient in Phase 1 trial of cetuximab biosimilar HLX05-N in ChinaPUBT·Jul 8 at 04:25 AM026960.00%
Is Shanghai Henlius Biotech (SEHK:2696) Pricey Or Undervalued After Its Canada Denosumab Launch?Simplywall·Jul 2 at 07:04 AM026960.00%
Shanghai Henlius doses first patient in Phase 1 HLX48 trial for advanced solid tumors in ChinaPUBT·Jun 30 at 04:14 AM026960.00%
Shanghai Henlius says first US patient dosed in Phase 1 trial of ipilimumab biosimilar HLX13 for advanced liver cancerPUBT·Jun 25 at 05:21 AM026960.00%SDZNY+3.13%
